Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration. Issue 2 (13th November 2013)

• Record Type: Journal Article
• Authors: Danis, Ronald; McLaughlin, Megan M; Tolentino, Michael; Staurenghi, Giovanni; Ye, Li; Xu, Chun-Fang; Kim, Robert Y; Johnson, Mark W
• Other Names: Reichel Elias author non-byline.; Glazer Louis author non-byline.; Ciulla Thomas author non-byline.; Menchini Ugo author non-byline.; Vaona Paola author non-byline.; Pearlman Joel author non-byline.; Midena Edoardo author non-byline.; Introini Ugo author non-byline.; Arnold Jennifer author non-byline.; Boyer David author non-byline.; Wong Tien author non-byline.; Hudson Henry author non-byline.; Guymer Robyn author non-byline.; Bernstein Paul author non-byline.; Leys Anita author non-byline.; Berger Brian author non-byline.; Greven Craig author non-byline.; Mitchell Paul author non-byline.; Constable Ian author non-byline.
• Is Part Of: British journal of ophthalmology. Volume 98:Issue 2(2014)
• Page Start: 172
• Page End: 178
• Publication Date: 2013-11-13
• Subjects: Clinical Trial -- Diagnostic tests/Investigation -- Drugs -- Macula -- Neovascularisation; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjophthalmol-2013-303117
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Aims: To evaluate pazopanib eye drops in patients with subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Methods: 70 patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to 5 mg/mL TID, 2 mg/mL TID, and 5 mg/mL QD pazopanib eye drops for 28 days in a multicentre, double-masked trial with an optional safety extension for up to 5 additional months. The primary outcomes were central retinal thickness (CRT) and best-corrected visual acuity (BCVA) at Day 29. Results: No significant decrease from baseline in CRT was observed overall; however, an exploratory analysis showed improvement in CRT (mean decrease of 89 μm) in patients with the CFH TT genotype who received 5 mg/mL TID (p=0.01, n=5). Mean increases in BCVA were observed in the 5 mg/mL TID overall (4.32 letters (p=0.002, n=26)) and in those that with CFH Y402H TT (6.96 letters (p=0.02, n=5)) and CT (4.09 letters (p=0.05, n=9)) genotypes. No safety signals that precluded continued investigation were detected. Conclusions: 5 mg/mL pazopanib eye drops resulted in mean improvement in BCVA at Day 29 and improvements in vision. However, improvement in macular oedema for age-related macular degeneration was found only in the subset of subjects with the CFH Y402H TT genotype, warranting further investigation.